Results 161 to 170 of about 16,272 (302)

Regulatory options for the market of designer drugs

, 2011
This paper describes an analyses the market of "legal" drugs, so called designer drugs, which emerged in Czech republic by the end of 2010, in other European countries about a year earlier.
Turek, Tomáš
core   +1 more source

High-Speed Identification of Designer Drugs by Multiple Mass Spectrometry

CHIMIA, 2005
Stephan Kölliker, Michael Oehme
doaj   +1 more source

Exon 7 splicing of ERα predicts poor prognosis and increases phenotypic heterogeneity in luminal a subtype breast cancer

FEBS Open Bio, EarlyView.
ERα splice variant ERα∆7 lacks the C‐terminus, and its expression may change phenotypes of breast cancers. Our results showed that ERα∆7 is found in the luminal A subtype, and elevated ERα∆7 levels are linked to improved cell survival with lower proliferation and migration.
Long Wai Tsui, Taobo Hu, Thomson Christian Husein, Wai Hei Shek, Bingrong Chen, Depeng Wang, Shu Wang, Weichuan Yu, Xiaodan Fan, Mengping Long, Toyotaka Ishibashi   +10 more
wiley   +1 more source

Development of human monoclonal antibodies against TARM1 by yeast display

FEBS Open Bio, EarlyView.
Human monoclonal antibodies against TARM1 are generated by yeast display‐guided selection. These antibodies bind to soluble and cell‐surface forms of TARM1. Also, these antibodies exhibit agonistic activity in the NFAT‐GFP reporter assay, indicating that TARM1 signaling can be functionally modulated by antibodies and suggesting TARM1 as a potential ...
Rikio Yabe, Mayumi Saeki, Masaaki Hashiguchi, Sayaka Ono, Kazuhisa Aoki, Hidetaka Tanno   +5 more
wiley   +1 more source

Conformational Restriction of Designer Drugs Reveals Subtype-Selective and Biased CB₂ Agonists with Neuroprotective Effects. [PDF]

J Med Chem
Gioé-Gallo C, Ortigueira S, Prieto-Díaz R, Contino M, Azuaje J, Perrone MG, Riganti C, Alberga D, Mangiatordi GF, Andújar-Arias A, García-Rey A, Graziano G, Stefanachi A, Val C, Martínez AL, Rebassa JB, Reza D, Selas A, Francavilla F, Paleo MR, García-Mera X, Loza MI, Navarro G, Brea J, Sotelo E.   +24 more
europepmc   +1 more source

Designer drugs and sexual dysfunction. [PDF]

Cent European J Urol, 2015
Benyó M.
europepmc   +1 more source

The attitudes of young people to the non-use or use of drugs and to drugs education and prevention strategies

, 1995
This thesis was submitted for the degree of Doctor of Philosophy and awarded by Brunel University.The study explores the attitudes of young people in the later years of their secondary education to the non-use or use of drugs and to the drugs education ...
Twigg, Barry
core  

Analysing the significance of small conformational changes and low occupancy states in serial crystallographic data

FEBS Open Bio, EarlyView.
This protocol paper outlines methods to establish the success of a time‐resolved serial crystallographic experiment, by means of statistical analysis of timepoint data in reciprocal space and models in real space. We show how to amplify the signal from excited states to visualise structural changes in successful experiments.
Jake Hill, Yelyzaveta Pulnova, Elke De Zitter, Helen M. Ginn, Briony A. Yorke   +4 more
wiley   +1 more source

Polydrug fatal intoxication involving MDPHP: Detection and in silico investigation of multiple 3,4-methylenedioxy-derived designer drugs and their metabolites. [PDF]

J Anal Toxicol
Casati S, Ravelli A, Dei Cas M, Bergamaschi RF, Vanerio S, Sicuro L, Faraone C, Rossi M, Galante N, Mollica L, Roda G, Rota P, Battistini A.   +12 more
europepmc   +1 more source

The newest cathinone derivatives as designer drugs: an analytical and toxicological review. [PDF]

Forensic Toxicol, 2018
Majchrzak M, Celiński R, Kuś P, Kowalska T, Sajewicz M.   +4 more
europepmc   +1 more source